Covered recipient · General Payments record
FADI BASHOUR
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$1,265.23
- Reported across 55 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $400.85 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Caldera Medical, Inc | $146.73 | 2 |
| ABBVIE INC. | $95.42 | 5 |
| Merck Sharp & Dohme Corporation | $37.50 | 2 |
| Ardelyx, Inc. | $35.38 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.80 | 1 |
| QOL Medical, LLC | $19.05 | 1 |
| Organon LLC | $15.34 | 1 |
| Madrigal Pharmaceuticals | $15.13 | 1 |
| Janssen Biotech, Inc. | $14.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.45 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103287557 | CMS |
| ABBVIE INC. | $15.93 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103287559 | CMS |
| ABBVIE INC. | $19.28 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103287561 | CMS |
| ABBVIE INC. | $25.62 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103287563 | CMS |
| ABBVIE INC. | $14.14 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103287565 | CMS |
| Ardelyx, Inc. | $17.58 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146670781 | CMS |
| Ardelyx, Inc. | $17.80 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146670783 | CMS |
| Caldera Medical, Inc | $104.50 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136347359 | CMS |
| Caldera Medical, Inc | $42.23 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136346625 | CMS |
| Janssen Biotech, Inc. | $14.50 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078488567 | CMS |
| Madrigal Pharmaceuticals | $15.13 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144161351 | CMS |
| Merck Sharp & Dohme LLC | $20.55 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141681811 | CMS |
| Merck Sharp & Dohme LLC | $16.95 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141681809 | CMS |
| Organon Llc | $15.34 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136227763 | CMS |
| QOL Medical, LLC | $19.05 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147724766 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.80 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137482250 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.